Form 4: Revolution Medicines Executive Sells Shares Under 10b5-1 Plan

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold shares of common stock and exercised stock options under a pre-arranged 10b5-1 trading plan.

Summary

• Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, executed transactions involving the company's stock on November 13, 2024.
• These transactions included the acquisition of 16,666 shares of common stock through the exercise of stock options at a price of $4.09 per share.
• Kelsey also sold 13,778 shares at a weighted average price of $58.4856 and 2,888 shares at a weighted average price of $59.4509.
• These transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on March 15, 2024.
• Following these transactions, Kelsey directly owns 264,408 shares of common stock, which includes 86,400 restricted stock units, and 6,666 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy. There is no indication of positive or negative sentiment from the document itself.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a common practice for executives to avoid accusations of insider trading.

Negatives

• The sale of shares by a high-ranking executive could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• Executive stock sales can sometimes be interpreted as a lack of confidence in the company's future prospects, although this is not necessarily the case with pre-planned 10b5-1 trading plans.

Management Comments

• The transactions were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and the use of 10b5-1 trading plans is a standard practice to manage insider trading risks.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Revolution Medicines.
• Companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also see similar filings from their executives.
• The reported prices are within the typical range for stock transactions of this nature.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, but the pre-planned nature of the sales mitigates any significant negative perception.

Key Dates

Keywords

Revolution Medicines, RVMD, Stephen Michael Kelsey, stock options, 10b5-1 trading plan, insider trading, executive stock sales, SEC Form 4